A K Anand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
A K Anand has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
A K Vaid
2 shared publicationsA R Chaudhoory
2 shared publicationsJ. Jain
2 shared publicationsP. Agarwal
2 shared publicationsP.S. Negi
2 shared publicationsR K Munjal
2 shared publications
Latest Publications
- Open Access
- 1 May 2017
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 123, S635
EP-1169: Preoperative CT scan in tumor bed delineation after breast conserving surgery and oncoplasty
- 1 May 2017
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 123, S635
Open AccessEP-1169: Preoperative CT scan in tumor bed delineation after breast conserving surgery and oncoplasty
- 1 July 2012
- Vol. 110 (7) , 462-4
Stereotactic body radiation therapy (SBRT) for lung and liver tumours.
- 1 July 2012
- Vol. 110 (7) , 462-4
Stereotactic body radiation therapy (SBRT) for lung and liver tumours.
- 1 November 2008
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 81 (971) , 865-871
Favourable impact of intensity-modulated radiation therapy on chronic dysphagia in patients with head and neck cancer
The aim of this study was to evaluate the impact of intensity-modulated radiation therapy (IMRT) on the incidence and severity of chronic dysphagia in patients with head and neck cancer. 62 evaluable patients with head and neck cancer who were treated with IMRT with or without concurrent chemotherapy were analysed. The majority of the patients (77.4%) had advanced locoregional disease. 45 patients underwent definitive IMRT and 17 received post-operative IMRT. Concurrent chemotherapy was given to 29 of the 45 patients treated with definitive IMRT. The average prescribed dose to clinical target volume (CTV)1 was 66–70 Gy (definitive IMRT) and 56–62 Gy (post-operative IMRT); 60 Gy to CTV2; 54 Gy to CTV3; and 50–52 Gy to the supraclavicular area. At a median follow-up of 19 months, 2-year actuarial locoregional control and survival was 77% and 74%, respectively. At 6 months after IMRT, chronic dysphagia was Grade 0 in 77.1% of patients, Grade 1 in 10.5% and Grade 2 in 12.3%. Acute mucositis showed no correlation with long-term dysphagia. The percutaneous endoscopic gastrostomy or nasogastric tube was removed in all of the patients within 8 weeks of completion of treatment. Xerostomia was Grade 0 in 61.4% of patients, Grade 1 in 31.5% and Grade 2 in 7% of patients. In conclusion, IMRT conferred a major favourable impact on chronic dysphagia in patients with locally advanced head and neck cancers, with satisfactory locoregional control.
- 1 November 2008
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 81 (971) , 865-871
Favourable impact of intensity-modulated radiation therapy on chronic dysphagia in patients with head and neck cancer
The aim of this study was to evaluate the impact of intensity-modulated radiation therapy (IMRT) on the incidence and severity of chronic dysphagia in patients with head and neck cancer. 62 evaluable patients with head and neck cancer who were treated with IMRT with or without concurrent chemotherapy were analysed. The majority of the patients (77.4%) had advanced locoregional disease. 45 patients underwent definitive IMRT and 17 received post-operative IMRT. Concurrent chemotherapy was given to 29 of the 45 patients treated with definitive IMRT. The average prescribed dose to clinical target volume (CTV)1 was 66–70 Gy (definitive IMRT) and 56–62 Gy (post-operative IMRT); 60 Gy to CTV2; 54 Gy to CTV3; and 50–52 Gy to the supraclavicular area. At a median follow-up of 19 months, 2-year actuarial locoregional control and survival was 77% and 74%, respectively. At 6 months after IMRT, chronic dysphagia was Grade 0 in 77.1% of patients, Grade 1 in 10.5% and Grade 2 in 12.3%. Acute mucositis showed no correlation with long-term dysphagia. The percutaneous endoscopic gastrostomy or nasogastric tube was removed in all of the patients within 8 weeks of completion of treatment. Xerostomia was Grade 0 in 61.4% of patients, Grade 1 in 31.5% and Grade 2 in 7% of patients. In conclusion, IMRT conferred a major favourable impact on chronic dysphagia in patients with locally advanced head and neck cancers, with satisfactory locoregional control.
- 1 June 2007
- Vol. 55, 451-2
Isolated intraorbital metastasis in breast carcinoma.
We report a case of metastases to the eye, in a 30 year old lady with carcinoma breast leading to isolated metastatic involvement of the lateral rectus muscle with no evidence of metastases at any other site in the body after a follow up of one year after completion of chemotherapy.
- 1 June 2007
- Vol. 55, 451-2
Isolated intraorbital metastasis in breast carcinoma.
We report a case of metastases to the eye, in a 30 year old lady with carcinoma breast leading to isolated metastatic involvement of the lateral rectus muscle with no evidence of metastases at any other site in the body after a follow up of one year after completion of chemotherapy.
- 1 August 2006
- Published by Elsevier in Clinical Oncology
- Vol. 18 (6) , 497-504
Can Dose Reduction to One Parotid Gland Prevent Xerostomia? — A Feasibility Study for Locally Advanced Head and Neck Cancer Patients Treated with Intensity-modulated Radiotherapy
- 1 August 2006
- Published by Elsevier in Clinical Oncology
- Vol. 18 (6) , 497-504
Can Dose Reduction to One Parotid Gland Prevent Xerostomia? — A Feasibility Study for Locally Advanced Head and Neck Cancer Patients Treated with Intensity-modulated Radiotherapy
- 1 June 2003
- Published by Elsevier in Clinical Oncology
- Vol. 15 (4) , 186-188
Pericardial Synovial Sarcoma
- 1 June 2003
- Published by Elsevier in Clinical Oncology
- Vol. 15 (4) , 186-188
Pericardial Synovial Sarcoma